Immunovant, Inc.
- IMVT
- NASDAQ
- Biotechnology
- Monoclonal Antibody Therapies
- Autoimmune Disease Treatments
$26.73
Today −2.84%Quote Oct 16, 2026, 08:00 PM UTC
−29.00%over the last month
Max drawdown −29.0%From 1-month high −29.0%3 months −33.0%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Market value
$5.52B
Quote Oct 16
Next earnings
Nov 9
Expected, not confirmed
Analyst target
$40.00
+49.6% from here
Floor
$25.69
3.9% below price
Where the price sits
No analyst target range for this stock.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about IMVTPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days freeWhere the money comes from
No revenue split by segment on file.
Industry
Biotechnology
Employees
315